ପାଲୋନୋସେଟ୍ରନ

ପାଲୋନୋସେଟ୍ରନ
Clinical data
Pronunciation	/pæləˈnoʊsətrɒn/ pal-ə-NOH-sə-tron
Trade names	Aloxi
AHFS/Drugs.com	monograph
MedlinePlus	a610002
data	EU EMA: yes; US DailyMed: Palonosetron;
Pregnancy; category	AU: B1 ; ;
Routes of; administration	Intravenous, by mouth
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	97% (oral)
Protein binding	62%
Metabolism	Liver, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)
Elimination half-life	Approximately 40–50 hours
Excretion	Kidney, 80% (of which 49% unchanged); fecal (5 to 8%)
Identifiers
	IUPAC name (3aS)-2-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one;
Chemical and physical data
Formula	C19H24N2O
Molar mass	୨୯୬.୪୧ g·mol−1
3D model (JSmol)	Interactive image;
Specific rotation	[α]D −136°; [α]D –94.1° (HCl)
Melting point	87 to 88 °C (189 to 190 °F)
	SMILES O=C5N([C@H]2C1CCN(CC1)C2)C[C@@H]4c3c5cccc3CCC4;
	InChI InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1 ; Key:CPZBLNMUGSZIPR-NVXWUHKLSA-N ;
(verify)

ପାଲୋନୋସେଟ୍ରନ (ଇଂରାଜୀ ଭାଷାରେ Palonosetron), ଆଲୋକ୍ସି ଏହାର ଏକ ବିକ୍ରୟ ନାମ ହେଉଛି ଏକ ଔଷଧ ଯାହାକି କେମୋଥରାପି ଜନିତ ଅଇ ଓ ବାନ୍ତି ଏବଂ ଅସ୍ତ୍ରୋପଚାର ପରବର୍ତ୍ତୀ ଅଇ ତ‌ଥା ବାନ୍ତିର ପ୍ରତିଷେଧ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ^[୨] ବିଳମ୍ବିତ ସିଆଇଏନଭି (CINV)ରେ ପରୀକ୍ଷାମୂଳକ ତଥ୍ୟ ଅଛି ଯାହା ଗ୍ରାନିସେଟ୍ରନ୍ ଅପେକ୍ଷା ଅଧିକ ପ୍ରଭାବଶାଳୀ ହୋଇପାରେ । ଏହା ପାଟିରେ କିମ୍ବା ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଇପାରେ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କ୍ୟୁଟି ବିସ୍ତାର, ମନ୍ଥର ହୃତ୍‌ସ୍ପନ୍ଦନ, ମୁଣ୍ଡବିନ୍ଧା, କୋଷ୍ଠକାଠିନ୍ୟ ଏବଂ ଦୁର୍ବଳତା ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲାକ୍‌ସିସ ଏବଂ ସେରୋଟୋନିନ୍ ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ନିରାପଦ ମନେହୁଏ, କିନ୍ତୁ ଏହିପରି ବ୍ୟବହାର ଭଲ ଭାବରେ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ ।^[୪] ଏହା ଏକ ୫-ଏଚଟି <sub id="mwIA">୩</sub> ବିରୋଧୀ ।^[୩]

୨୦୦୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୦୫ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ପାଲୋନୋସେଟ୍ରନ୍ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ^[୧] ଓନଡାନ୍‌ସେଟ୍ରନ୍‌ର ବିକଳ୍ପ ଭାବରେ ଏହା ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରେ ଅଛି ।^[୫] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ଏକ ମାତ୍ରା ପିଛା ପ୍ରାୟ ୫୫ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୫୦ ଡଲାର ଅଟେ ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Aloxi". Archived from the original on 14 April 2021. Retrieved 25 October 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Palonosetron Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 25 October 2021.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 456. ISBN 978-0857114105.
↑ "Palonosetron (Aloxi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 November 2020. Retrieved 25 October 2021.
↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
↑ "Palonosetron Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 25 October 2021.

[EPAR2021-1] ୧.୦ ^୧.୧ "Aloxi". Archived from the original on 14 April 2021. Retrieved 25 October 2021.

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Palonosetron Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 25 October 2021.

[BNF81-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 456. ISBN 978-0857114105.

[4] "Palonosetron (Aloxi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 November 2020. Retrieved 25 October 2021.

[WHO22nd-5] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[6] "Palonosetron Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 25 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

Clinical data

Pronunciation	/pæləˈnoʊsətrɒn/ pal-ə-NOH-sə-tron
Trade names	Aloxi
AHFS/Drugs.com	monograph
MedlinePlus	a610002
data	EU EMA: yes US DailyMed: Palonosetron
Pregnancy category	AU: B1
Routes of administration	Intravenous, by mouth
Legal status
Legal status	US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	97% (oral)
Protein binding	62%
Metabolism	Liver, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)
Elimination half-life	Approximately 40–50 hours
Excretion	Kidney, 80% (of which 49% unchanged); fecal (5 to 8%)
Identifiers
IUPAC name (3aS)-2-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one
Chemical and physical data
Formula	C₁₉H₂₄N₂O
Molar mass	୨୯୬.୪୧ g·mol⁻¹
3D model (JSmol)	Interactive image
Specific rotation	[α]_D −136° [α]_D –94.1° (HCl)
Melting point	87 to 88 °C (189 to 190 °F)
SMILES O=C5N([C@H]2C1CCN(CC1)C2)C[C@@H]4c3c5cccc3CCC4
InChI InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1^Y Key:CPZBLNMUGSZIPR-NVXWUHKLSA-N^Y
(verify)